A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer

A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer

Abstract Background Prevention of unnecessary biopsies and overtreatment of indolent disease remains a challenge in the management of prostate cancer. Novel non-invasive tests that can identify clinically significant (intermediate-risk and high-risk) diseases are needed to improve risk stratificatio...

Full description

Bibliographic Details
Main Authors: Fang Zhao, Ekaterina Olkhov-Mitsel, Shivani Kamdar, Renu Jeyapala, Julia Garcia, Rachel Hurst, Marcelino Yazbek Hanna, Robert Mills, Alexandra V. Tuzova, Eve O’Reilly, Sarah Kelly, Colin Cooper, The Movember Urine Biomarker Consortium, Daniel Brewer, Antoinette S. Perry, Jeremy Clark, Neil Fleshner, Bharati Bapat
Format: Article
Language:English
Published: BMC 2018-11-01
Series:Clinical Epigenetics
Subjects:
Prostate cancer
PSA
Urine
DNA methylation
Biomarker
Early detection
Online Access:http://link.springer.com/article/10.1186/s13148-018-0575-z

Internet

http://link.springer.com/article/10.1186/s13148-018-0575-z

Similar Items